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A benign, non-neoplastic, reactive growth of 
the liver, focal nodular hyperplasia (FNH) of the 
liver was first clearly described by Edmondson in 
the 1950’s, although there are various prior reports 
that likely represent the same lesion. A variety of 
synonyms have been applied including focal cirrhosis, 
pedunculated adenoma, solitary hyperplastic nodule, 
mixed adenoma, hamartoma and hamartomatous 
cholangeiohepatoma. FNH is the most frequent 
benign, solid hepatic tumor and, after hemangioma, 
the second most common benign lesion.1 In an 
autopsy series comprising 96,625 patients, Craig et al.2 
identified 8% of non-hemangiomatous hepatic lesions 
as FNH. The various labels applied over the years have 
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mostly been reflections of its’ histopathology. In 1994 
the nomenclature was standardized, placing FNH in the 
group of regenerative nodules, differentiating it from 
dysplastic or neoplastic lesions.3
The reported prevalence of FNH in the general 
population ranges between 0.4 to 3%, probably 
increasing with age.1 Although, this entity may be 
found throughout the age spectrum, diagnosis is 
predominantly made between 20 and 50 years. The 
female: male ratio is 8 or 9:1, in as many as 80% of 
cases there is a single, well defined, but generally 
non-encapsulated lesion that can be as large as 20 cm 
diameter but generally is between 4 to 8 cm.4,5
The most characteristic macroscopic feature is the 
central, stellate fibrovascular zone, as easily seen in the 
image, which has the historically entrenched names of 
“central scar,” “fibrous scar” or “scar-like fibrosis”.6
The central scar usually consists of mature collagen 
and numerous vascular channels, many of which 
are medium and large thick-walled arteries which 
often show fibromuscular hyperplasia, myointimal 
proliferation and myxomatous change, sometimes 
with significant luminal narrowing.6 True portal tracts 
are not seen but marginal bile ductular proliferation 
is common and can be very helpful in establishing the 
diagnosis in biopsy material (see below).
The pathogenesis is not fully understood, but it 
is highly accepted that an arterial abnormality, often 
a malformation, causing hypo- or hyperperfusion, 
which triggers reactive hyperplasia of otherwise normal 
hepatocytes.7-10 This hypothesis is strengthened by 
the association of FNH with hereditary hemorrhagic 
telangiectasia (Osler-Weber-Rendu disease) and hepatic 
hemangiomas.4,10 However a vascular malformation 
is not identified in all FNHs. Indeed, some lack a 
dominant feeding artery and are hypovascular or have a 
peripheral rather than a central blood supply. The liver 
cells of FNH have been shown to be polyclonal in more 
than 50% of cases. No somatic mutations in genes 
have, thus far, been identified in FNH cases.5 A genetic 
predisposition to the disease has been suggested by 
the documentation of FNH in identical twins11 but there 
has been no confirmation of this concept.
Gene express ion studies have,  however, 
demonstrated molecular features supporting the 
concept of vascular abnormalities as the principal 
etiopathogenetic factor; FNH can have increased 
expression of ANGPT1, classically responsible for vessel 
formation, and ANGPT2, an antagonist to ANGPT1.12 
The increased expression of these two genes is 
associated with angiogenesis. Genomic expression 
studies have shown overexpression of several genes, 
particularly of the central fibrous scar, relating to 
activation of the transforming growth factor β (TGF β) 
pathway. Glutamine synthetase (GS) overexpression is 
also seen and can be useful in the biopsy identification 
of the lesion13 showing a typical map-like pattern of 
distribution at the periphery of the nodules.
The diagnosis of FNH can be particularly challenging 
in biopsy material if the central scar is not included 
in the sample.6,13 Hepatocytes are almost always 
cytologically bland but may show mild degenerative 
change, focal steatosis or increased glycogen. The 
liver cells are arranged in one- or two-cell thick plates 
and can form incomplete nodules or pseudonodules 
sometimes surrounded by slender, fibrous septa, which 
extend from the central scar but are not always seen 
in biopsy samples. In biopsy, when the fibrous scar 
is absent and there are no bile duct-like structures, 
distinction of FNH from hepatic adenoma is aided 
by molecular studies confirming that FNH lesions are 
polyclonal with β-catenin activation without mutation14 
as well as GS immunostaining.12,13
Larger and more symptomatic lesions are observed 
among patients taking oral contraceptives (OCP). 
Although FNH may be responsive to estrogens, it is 
clear that the use of OCPs is not required for the 
development of FNH.15
Usually asymptomatic (80% of the cases), FNH 
not infrequently is incidentally diagnosed due to 
widespread use of radiologic examinations, as a mass 
noted at the time of a surgery or at autopsy. This lesion 
rarely grows or bleeds and has no malignant potential.16 
Symptoms when present are vague and nonspecific. 
Most series report abdominal discomfort, pain or a liver 
palpable mass. Fever is present in less than 1 percent 
of cases. Liver function tests and α-fetoprotein are 
normal but minor elevations of aspartate and alanine 
aminotransferase, alkaline phosphatase and gamma 
glutamyl transpeptidase may be seen.4,17
In the past, this tumor was resected due to the 
difficulty in distinguishing it from hepatic adenoma, 
but nowadays, with the improvement of imaging 
techniques and with a combination of imaging 
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modalities it is now almost always accurately diagnosed 
with imaging and is not resected.
The evaluation of FNH by ultrasound (US) has 
a low sensitivity, however the lesion appears as a 
well demarcated, homogeneous and isoechoic mass 
relative to the liver parenchyma with a hyperechoic 
central scar.4,18 Some lesions may show a hypoechoic 
surrounding halo.19 The color and power Doppler US 
may furnish additional information on the vascularity 
of the suspected FNH.19 Triphasic helical computed 
tomography scan performed without contrast, and 
with contrast during the hepatic arterial and portal 
venous phases will often be highly suggestive of the 
diagnosis. The typical lesion has lobulated contour19 
and may be hypo or isodense on non-contrast imaging 
with the central scar identified in one-third of patients. 
Rarely calcifications may be present within the central 
scar.20 The lesion becomes hyperdense during the 
hepatic arterial phase due to the arterial origin of its 
blood supply. During the portal venous phase the lesion 
becomes generally isodense, although the central scar 
may become hyperdense as contrast diffuses into the 
scar.17,19 In large lesions feeding arteries may be seen 
penetrating the central scar as well as draining veins at 
the surface of the tumor.1 On MRI, FNH is isointense to 
mildly hypointense on T1-weighted images (94-100%) 
and is isointense to mildly hyperintense on T2-weighted 
images (94-100%).19 The lesion shows homogeneous-
intense arterial phase enhancement and isointensity 
on the venous and delayed-phase images.19 The scar 
characteristics (hyperintense on T2-weighted – 84%)19 
and lack of capsule enhancement help to distinguish 
FNH from other arterial-phase enhancing tumors, 
such as hepatocellular carcinoma (HCC), adenoma, 
and fibrolamellar HCC. Accurate differentiation of 
FNH from hepatic adenoma is achievable on delayed 
T1-weighted gradient-echo sequences images after 
administration of gadobenate dimeglumine. The 
sensitivity and specificity of FNH from adenoma reach 
97% and 100%, respectively.21-24
Differential diagnosis of FNH comprises other 
hepatic tumors that present generally as single 
solid lesions, and their differentiation is crucial 
because of diverse therapeutic approaches and 
prognosis. Unfortunately, the distinction is not 
always straightforward, particularly with small 
lesions. Nevertheless, even in the presence of 
diagnostic evidences, the differential diagnosis should 
include: hepatic adenoma, HCC, Fibrolamellar HCC, 
hypervascular metastases, hemangioma and even 
focal steatosis.6
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